Evelo Biosciences - EVLO Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EVLO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EVLO, but not buy additional shares or sell existing shares.
View EVLO analyst ratings or view top-rated stocks.

4 equities research analysts have issued 12-month price targets for Evelo Biosciences' shares. Their EVLO share price forecasts range from $2.00 to $5.00. On average, they anticipate the company's share price to reach $3.17 in the next year. This suggests a possible upside of 1,166.7% from the stock's current price.
View analysts price targets for EVLO or view top-rated stocks among Wall Street analysts.

Evelo Biosciences' stock was trading at $1.61 at the beginning of the year. Since then, EVLO stock has decreased by 84.5% and is now trading at $0.25.
View the best growth stocks for 2023 here.

Evelo Biosciences saw a decrease in short interest in the month of February. As of February 28th, there was short interest totaling 2,740,000 shares, a decrease of 22.2% from the February 13th total of 3,520,000 shares. Based on an average trading volume of 132,200 shares, the short-interest ratio is currently 20.7 days.
View Evelo Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our EVLO earnings forecast.

Evelo Biosciences, Inc. (NASDAQ:EVLO) issued its quarterly earnings data on Wednesday, October, 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by $0.09. During the same period in the prior year, the company posted ($0.45) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

(EVLO) raised $85 million in an initial public offering on Wednesday, May 9th 2018. The company issued 5,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

Evelo Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.56%), Mayo Clinic (0.44%), Mayo Clinic (0.44%), Susquehanna International Group LLP (0.14%), Trustees of Columbia University in the City of New York (0.11%) and Citigroup Inc. (0.09%). Insiders that own company stock include David R Epstein, Stephen J Carriere, Ventures Fund Iv Gene Flagship and Xiaoli Jacqueline Liu.
View institutional ownership trends.

Shares of EVLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EVLO stock can currently be purchased for approximately $0.25.

Evelo Biosciences (NASDAQ:EVLO) has a market capitalization of $27.00 million. The company earns $-122,180,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis.

The company employs 122 workers across the globe.

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The official website for the company is www.evelobio.com. The company can be reached via phone at (617) 577-0300 or via email at ir@evelobio.com.